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*Staphylococcus aureus* is a major human pathogen that possesses multiple toxins and virulence mechanisms ([@R-2-1]). Antimicrobial drug resistance in *S. aureus* has added to the complexity of treating serious infections caused by this bacteria, and methicillin-resistant *S. aureus* (MRSA) appears to have greater virulence than methicillin-susceptible strains ([@R-2-2],[@R-2-3]). Most MRSA strains in the United States are pulsed-field gel electrophoresis (PFGE) types USA100 and USA300, corresponding to multilocus sequence typing (MLST) ST5 and ST8, respectively ([@R-2-4]). MRSA belonging to MLST ST239 and harboring staphylococcal cassette chromosome *mec* (SCC*mec*) type III (MRSA ST239-III) are associated with infections in health care settings, outbreaks, increased resistance to antimicrobial drugs, and capacity for invasive disease ([@R-2-5]--[@R-2-7]).

MRSA ST239-III has a history of successful dissemination in many regions, leading to a diverse array of regionally prevalent clones. These clones include the Brazilian; British Epidemic 1, 4, 7, 9, and 11; Canadian Epidemic 3/Punjab; Czech; Eastern Australian 2 and 3; Georgian; Hungarian; Lublin; Nanjing/Taipei (ST241); Portuguese; and Vienna clones ([@R-2-8],[@R-2-9]). Although it is common worldwide, MRSA ST239-III has not played any predominant role in the United States; infections with MRSA ST239-III have been rarely reported in the United States since the 1990s ([@R-2-9]--[@R-2-13]). Recently, only 2 reports of this strain in the United States involving sporadic nasal colonization and bloodstream infections have been published ([@R-2-13],[@R-2-14]).

In this study, we describe clinical epidemiologic characteristics and molecular analysis of clinical infections with MRSA ST239-III in the midwestern United States. Identification of a strain from such a virulent clonal group in the United States with wide dissemination in other parts of the world represents a potential public health concern.

Methods
=======

Sampling Method
---------------

As part of Centers for Disease Control and Prevention (CDC) (Atlanta, GA, USA)--sponsored Prevention Epicenter Program study evaluating the transmission of MRSA between hospitals in Ohio, USA, molecular analysis was performed on a group of clinical MRSA isolates collected from The Ohio State Health Network (OSHN). The OSHN consists of The Ohio State University (OSU) Wexner Medical Center (WMC), which is a tertiary care medical center, and 7 smaller community hospitals located 30--120 miles from OSU. All MRSA specimens from community hospitals and selected OSU MRSA blood isolates and isolates from patients residing in the catchment areas of the outreach hospitals were prospectively collected during March 2009--February 2010 for genotyping by using a repetitive element PCR (rep-PCR). Among archived MRSA isolates from OSUWMC from January 2007 through February 2009, only a selection of isolates was chosen for genotyping (not a randomized sampling). The total number of isolates and the total number of ST239 from each time period was collected.

Data Collection
---------------

We performed medical record reviews for 1,286 patients. Patient demographic characteristics (presence of health care--related risk factors during the preceding 12 months, presence of an invasive device during the previous 7 days, and concurrent conditions) were collected. Patient-level data, including addresses for geocoding, were entered into a secure database within the OSUWMC Information Warehouse.

Classification of MRSA Infections
---------------------------------

All MRSA cases were classified into 3 categories on the basis of accepted epidemiologic definitions ([@R-2-11]). The first category was health care--associated, defined as a culture obtained \>48 hours after admission. The second category was health care--associated community onset, defined as a culture obtained [\<]{.ul}48 hours after admission with identified health care--associated risk factors. The third category was community-associated, defined as a culture obtained [\<]{.ul}48 hours after admission without health care--associated risk factors. Health care--associated risk factors comprised presence of an invasive device, history of MRSA infection or colonization, surgery, hospitalization, dialysis, or residence in a long-term care facility in the 12 months preceding the culture.

Outcomes for MRSA infection were categorized as cure (complete resolution after antimicrobial drug treatment); failure (persistence of infection and change in antimicrobial drug regimen); relapse (resolution of infection after complete treatment with subsequent development of new symptoms); recurrent (redevelopment of MRSA at same or other site [\>]{.ul}2 weeks after completion of treatment for initial MRSA infection); indeterminate (unknown outcome); and death (death [\<]{.ul}30 days after diagnosis of MRSA infection because of any cause or during the same hospitalization). Destination after hospital discharge, such as home or skilled nursing facility, was also noted.

Drug Susceptibility Testing
---------------------------

The respective OSHN Clinical Microbiology Laboratories initially identified all MRSA isolates by using standard microbiological methods. Antimicrobial drug susceptibility testing was performed at each institution, and results were interpreted according to Clinical and Laboratory Standards Institute break point guidelines ([@R-2-15]). At OSUWMC, antimicrobial drug susceptibility testing was performed by using the automated Micro-Scan method (Siemens Diagnostics, Sacramento, CA, USA), and only constitutive clindamycin testing was performed. Linezolid MIC \>4 mg/L were confirmed by using the Etest method (bioMérieux, Marcy l'Etoile, France).

Genotyping
----------

The MRSA ST239 III isolates were genotyped initially by using rep-PCR, followed by PFGE, staphylococcal protein A sequencing (*spa* typing), SCC*mec* typing, and *mec*-associated direct repeat unit (*dru*) typing. Selected isolates were also characterized by MLST and single-nucleotide polymorphism (SNP) typing. Detection of genes encoding Panton--Valentine leukocidin (PVL), toxic shock syndrome toxin (TSST), arginine catabolic mobile element (ACME), and high-level mupirocin resistance (*mupA*) was also performed. Brief descriptions of each testing method are outlined below.

### rep-PCR

The DiversiLab System (bioMérieux, Durham, NC, USA) was used for rep-PCR analysis according to described methods ([@R-2-16]). Isolates belonging to designated rep-PCR clusters shared \>95% similarity. In addition, comparison of matching patterns in the DiversiLab System library was initially used to infer the PFGE and SCC*mec* types, which were later validated by using appropriate testing methods. The numeric classification system used for rep-PCR analysis is unique to OSUWMC.

### PFGE

The PulseNet protocol for molecular subtyping of *S*. *aureus* was followed. *Salmonella enterica* serotype Braenderup DNA was digested with *Xba*I (Roche, Indianapolis, IN, USA) and used as the normalization standard for gel analysis. *S. aureus* chromosomal DNA was digested with *Sma*I (Roche). Fragments were separated in a clamped homogenous electric field mapper unit (Bio-Rad Laboratories, Hercules, CA, USA). Fingerprint images were analyzed by using Bionumerics software version 4.61 (Applied Maths NV, Sint-Martens-Latem, Belgium). The traditional classification of PFGE subtypes was not used because we were not analyzing for an outbreak ([@R-2-17]). Thus, interpretations of possibly or probably related PFGE subtypes between strains obtained by PFGE band patterns were not made. Each PFGE band difference was classified as a unique PFGE pattern.

### *spa* Typing

*spa* typing ([@R-2-18]) was performed on all MRSA isolates by using eGenomics software ([www.egenomics.com](http://www.egenomics.com)) as described ([@R-2-19]); Ridom *spa* types were subsequently assigned by using the SpaServer website ([www.spaserver.ridom.de](http://www.spaserver.ridom.de)).

### SCC*mec* Typing

SCC*mec* typing was performed on all MRSA isolates by using a described multiplex real-time PCR ([@R-2-20]). This PCR is specific for 2 essential gene complexes (*ccr* and *mec*) found in all SCC*mec* elements.

### *dru* Typing

MRSA isolates were also characterized by sequencing the hypervariable *dru* repeat region within the SCC*mec* element ([@R-2-21]) and using DruID software ([@R-2-9]). New *dru* types were submitted to [www.dru-typing.org](www.dru-typing.org).

### MLST and PVL, TSST, ACME, and Mupirocin Resistance

MLST was performed on representative isolates as described ([@R-2-22]) by using the MLST database (<http://saureus.mlst.net>). PCR-based detection of PVL ([@R-2-23]), TSST ([@R-2-24]), ACME ([@R-2-25]), and *mupA* ([@R-2-26]) was performed on all isolates as described.

### SNP Typing

A panel of 43 SNPs for describing the global population structure of MRSA ST239-III ([@R-2-9]) was used to identify the haplotypes of 22 isolates. These SNPs were typed by using Golden-Gate Genotyping Assay (Illumina, San Diego, CA, USA) and conventional Sanger sequencing.

Statistical Analysis
--------------------

All patient demographic, clinical, and molecular typing data were aggregated in tabular format, and descriptive statistics were generated by using SAS version 9.2 (SAS Institute Inc., Cary NC, USA), for demographic and risk factor history. A significant difference between ST239 and other strains (US300, US100, and all other strains) was examined by using χ^2^ tests for categorical variables and *t*-tests for continuous variables. An α level of 0.5 was used.

Human Subjects Protection
-------------------------

We obtained approval for this study from the OSU Office of Responsible Research Practices' Biomedical Institutional Review Board. The OSU Information Warehouse has established honest broker status with the OSU Institutional Review Board, enabling storage of fully identifiable data and presentation of patient data to investigators in a coded format that maintains patient confidentiality.

Results
=======

Patient Characteristics
-----------------------

Of 1,286 clinical MRSA isolates, 78 (6%) were identified as MRSA ST239-III; 71 (91%) were obtained from OSU and 7 (9%) from community hospitals. Seven (2%) of 397 isolates were obtained from outreach community hospitals, 37 (6%) of 613 from OSUWMC, and 34 (12%) of 276 from OSUWMC archives.

These strains were first recognized by rep-PCR as possible SCC*mecA* type III isolates from the DiversiLab System library with imputed Brazilian PFGE types. Additional molecular typing identified MRSA ST239-III in a clade different from that containing the Brazilian strains.

Demographics and clinical characteristics of 78 patients infected with MRSA ST239-III are shown in the Table. Among patients with MRSA ST239-III infections, 46 (59%) were male, 65 (83%) were white, 31 (40%) disabled, and 29 (37%) were retired. Seventy-four (95%) had health care--associated isolates and 51 (65%) had histories of use of invasive devices within the previous 7 days. Distribution of specimen types include 37 (47%) bloodstream infections (BSIs), 19 (24%) lower respiratory tract infections (LRTIs), 11 (14%) skin and soft tissue infections, and 11 (14%) other infections. Seventeen (22%) patients died, and 18 (23%) patients had treatment failures, recurring infections, or relapses. Only 32% of the patients were discharged home.

Comparison of clinical characteristics of MRSA ST239-III with those of PFGE types USA100 and USA300 and other non--ST239 infections are shown in the Table. Most ST239 isolates were health care--associated MRSA and had characteristics and concurrent conditions similar to those associated with USA100. MRSA ST239-III did not have virulent determinants often associated with health care--associated or community-associated MRSA strains, such as PVL, TSST, ACME, or *mupA*.

Characteristics of MRSA ST239-III Isolates
------------------------------------------

Resistance was observed to clindamycin (76/76, 100%), moxifloxacin (47/47, 100%), gentamicin (74/77, 96%), tetracycline (70/74, 95%), and trimethoprim--sulfamethoxazole (62/77, 81%). All MRSA ST239-III isolates were susceptible to vancomycin. For daptomycin, 64 (98%) of 65 isolates were susceptible, and 1 blood isolate with an MIC of 2 mg/L was classified as uninterpretable. For linezolid, 69 (97%) of 71 isolates were susceptible and 2 blood isolates with MICs \>4 mg/L were classified as uninterpretable.

Molecular Typing of MRSA ST239-III Isolates
-------------------------------------------

Eight rep-PCR patterns (6, 19, 22, 42, 53, 78, 79, and 97) were detected among MRSA ST239-III isolates, and 39 (50%) isolates had rep-PCR pattern 6. Similarly, isolates were distributed among 9 PFGE patterns (A, B, C, D, E, F, G, H, and I), and 58 (74%) had PFGE pattern A. The rep-PCR and PFGE patterns are shown in [Figure 1](#F-2-1){ref-type="fig"}. PFGE pattern F is \<80% similar with other PFGE subtypes in the dendrogram and was identified as an unknown PFGE type by the CDC database. However, molecular testing confirmed it to be MRSA ST239-III: MLST 239, SCC*mec* type III, *spa* type 3(t037), *dru* type dt15b, and SNP haplotype H9.

![Methicillin-resistant *Staphylococcus aureus* sequence type 239-III isolates, Ohio, USA, 2007--2009, based on A) repetitive element PCR (rep-PCR) and B) pulsed-field gel electrophoresis. Virtual gel results are shown for 8 DiversiLab System (bioMérieux, Durham, NC, USA) rep-PCR patterns. Pattern numbers assigned are unique to the Ohio State University Wexner Medical Center.](12-0468-F1){#F-2-1}

Four *spa t*ypes, including eGenomics *spa* types 3 (Ridom t037), 314 (t363), 121 (t421), and 1256 (t631) were identified, and 74 (95%) isolates were classified as *spa* type 3 (t037). In contrast, isolates were grouped into 13 *dru* types (dt2c, dt6n, dt9g, dt12i, dt13k, dt14 g, dt15b, dt15h, dt15i, dt15j, dt15k, dt16a, and dt23a), and 60 (77%) isolates were classified as dt15b. MLST typing of selected representative isolates confirmed 13 to be MRSA ST239-III (2-3-1-1-4-4-3), 3 as ST1801 (2-3-1-1-4-19-3), and 1 as ST2017 (2-3-1-1-4-19-227). ST1801 is a single-locus variant of MRSA ST239-III, and ST2017 is a novel single-locus variant of ST1801 and a double-locus variant of MRSA ST239. All were SCC*mec* type III, and the *ccrC* locus was not detected. The genes that encode PVL, TSST, ACME, or high-level mupirocin resistance were not found in any isolates.

A total of 33 unique genotypic combinations from 78 patients infected with MRSA ST239-III were represented among isolates with complete SCC*mec*, rep-PCR, PFGE, *spa*, and *dru* data. This information and year of isolation are shown in [Figure 2](#F-2-2){ref-type="fig"}. The genotype cluster sizes ranged from 2 to 18 isolates; 23 of the isolates were unique. In contrast, SNP typing of 22/78 isolates with a panel of 43 SNPs showed them to be indistinguishable from each other. All isolates tested belonged to haplotype 9 (H9) within MRSA ST239-III clade II ([Figure 3](#F-2-3){ref-type="fig"}). This clade was composed of isolates from many continents, including many from sources in Asia ([@R-2-9]).

![Molecular characteristics of 78 methicillin-resistant *Staphylococcus aureus* sequence type 239-III isolates, Ohio, USA, 2007--2009. SCC*mec*, staphylococcal cassette chromosome *mec*; *spa*, staphylococcal protein A; rep-PCR, repetitive element PCR; PFGE, pulsed-field gel electrophoresis; *dru*, direct repeat unit; dt, *dru* type. The 33 unique genotypic combinations are contrasted by black and gray shading.](12-0468-F2){#F-2-2}

![Single-nucleotide polymorphism (SNP) haplotype map showing position of methicillin-resistant *Staphylococcus aureus* sequence type 239-III (MRSA ST239-III) isolates, Ohio, USA, 2007--2009, within the global population structure of the MRSA ST239-III clonal group. Circles indicate distinct haplotypes, as defined by using a panel of 43 SNPs ([@R-2-9]). Sizes of circles indicate relative frequency of different haplotypes. Arrows indicate haplotype 5 (H5), which includes the Brazilian clone, and haplotype 9 (H9), which includes the 22 MRSA ST239-III isolates from Ohio. Relationships between haplotypes were determined by using maximum-parsimony analysis ([@R-2-9]).](12-0468-F3){#F-2-3}

Discussion
==========

MRSA ST239-III has demonstrated epidemic potential worldwide, and identification of this strain in the United States might represent a major public health concern. Although the precise time frame of emergence of this strain in Ohio is unknown, it appears to have been present before the study because it was identified in archived specimens dating back to 2007. The origin of the MRSA ST239-III clonal group has been dated to the mid-20th century in 2 studies ([@R-2-9],[@R-2-27]). Thus, the Ohio strain might have been introduced into the region anytime during the past 40 years. Because of incomplete sampling during the study, the transmission dynamics of Ohio MRSA ST239 III are uncertain. Whether the prevalence would have been \>6% if complete sampling was conducted is unknown. Furthermore, we found no epidemiologic evidence of clustering of cases consistent with an outbreak of infection with this strain. The large number of isolates at OSUWMC merely reflects its role as a large referral center.

Clinically, MRSA ST239-III is primarily health care associated, causes major outbreaks, shows increased resistance to antimicrobial drugs, and demonstrates a capacity for causing invasive disease ([@R-2-5]--[@R-2-7],[@R-2-28],[@R-2-29]). Comparison of characteristics of patients infected with MRSA ST239-III with those infected with PFGE USA300, PFGE USA100, and other strains showed that MRSA ST239-III is similar to USA100 in terms of health care--associated risk factors and outcomes ([Table](#T-2-1){ref-type="table"}).

###### Characteristics of 1,286 patients with MRSA ST239-III and non--MRSA ST239-III infections, Ohio, USA, 2007--2009\*

  Characteristic                                                      ST239, n = 78   USA100, n = 481   p value   USA300, n = 574   p value    All other, n = 153   p value
  ------------------------------------------------------------------- --------------- ----------------- --------- ----------------- ---------- -------------------- ----------
  Outreach hospital isolates                                          7 (9)           81 (17)           NA        262 (46)          NA         47 (31)              NA
  Patient demographics                                                                                                                                              
  Mean age, y (range)                                                 58 (19--90)     61 (18--99)       0.06      43 (18--92)       \<0.0001   49 (18--94)          0.001
  Male sex                                                            46 (59)         259 (54)          0.39      311 (54)          0.42       80 (52)              0.33
  White race                                                          65 (83)         393 (82)          0.85      441 (77)          0.61       126 (82)             0.77
  Medical history                                                                                                                                                   
  Diabetes                                                            33 (42)         149 (31)          0.047     116 (20)          \<0.0001   35 (23)              0.002
  Chronic lung disease                                                26 (33)         117 (24)          0.09      74 (13)           \<0.0001   17 (11)              \<0.0001
  Renal failure                                                       19 (24)         93 (19)           0.39      37 (6)            \<0.0001   17 (11)              0.008
  Malignancy                                                          13 (17)         97 (20)           0.47      48 (8)            0.02       30 (20)              0.58
  Health care--associated risk factors, past 12 mo                                                                                                                  
  Hospitalization                                                     58 (74)         296 (62)          0.03      148 (26)          \<0.0001   58 (38)              \<0.0001
  Use of invasive device                                              35 (45)         168 (35)          0.09      66 (12)           \<0.0001   35 (23)              0006
  Surgery                                                             35 (45)         179 (37)          0.19      79 (14)           \<0.0001   33 (22)              0.0002
  History of MRSA infection                                           26 (33)         77 (16)           0.0003    82 (14)           \<0.0001   29 (19)              0.015
  Stay in long-term care facility                                     22 (28)         155 (32)          0.47      34 (6)            \<0.0001   14 (9)               0.0002
  Hemodialysis                                                        15 (19)         47 (10)           0.068     18 (3)            \<0.0001   10(7)                0.015
  Other                                                               10 (13)         29 (6)            0.03      40 (7)            0.06       7 (5)                0.02
  Invasive devices [\<]{.ul}7 d before infection                                                                                                                    
  Central venous catheter                                             25 (32)         156 (32)          0.94      61 (11)           \<0.0001   32 (21)              0.06
  Foley catheter                                                      17 (22)         99 (21)           0.8       55 (10)           0.001      17 (11)              0.03
  Hemodialysis                                                        13 (17)         49 (10)           0.02      19 (3)            \<0.0001   8 (5)                0.008
  Mechanical ventilation                                              14 (18)         85 (18)           0.95      35 (6)            0.0002     11 (7)               0.012
  Drainage tubes                                                      8 (10)          50 (10)           0.97      10 (2)            \<0.0001   5 (3)                0.02
  Total parenteral nutrition                                          8 (10)          22 (5)            0.04      4 (1)             \<0.0001   0                    0.0001
  Other                                                               20 (26)         71 (15)           0.016     39 (7)            \<0.0001   15 (10)              0.0015
  Classification of MRSA infection                                                                                                                                  
  Health care associated                                              32 (41)         197 (41)          0.97      63 (11)           \<0.0001   37 (24)              0.01
  Health care associated community onset                              42 (54)         214 (44)          0.12      113 (20)          \<0.0001   49 (32)              0.0012
  Community associated                                                4 (5)           70 (15)           0.02      398 (69)          \<0.0001   67 (44)              \<0.0001
  Outcome                                                                                                                                                           
  Cure                                                                23 (29)         149 (31)          0.81      94 (16)           0.005      38 (25)              0.49
  Failure                                                             3 (4)           7 (1.5)           0.14      12 (2)            0.33       5 (3)                0.81
  Relapse                                                             4 (5)           7 (1.5)           0.03      2 (1)             0.0001     1 (1)                0.022
  Recurrent                                                           11 (14)         45 (9)            0.2       36 (6)            0.012      3 (2)                0.0002
  Indeterminate                                                       20 (26)         192 (40)          0.015     408 (71)          0.001      97 (63)              0.0001
  Death                                                               17 (22)         81 (17)           0.29      22 (4)            0.001      9 (6)                0.0003
  No. patients admitted                                               74              429               0.005     310               0.0003     111                  0.003
  Admitting service                                                                                                                                                 
  Intensive care unit                                                 14 (19)         58 (14)           0.2       29 (9)            0.019      9 (8)                0.047
  Medicine service                                                    31 (42)         238 (55)          0.03      203 (66)          0.0002     75 (68)              0.0007
  Surgery service                                                     20 (27)         117 (27)          0.95      59 (19)           0.12       20 (18)              0.126
  Other specialty care unit†                                          9 (12)          16 (4)            0.002     19 (6)            0.073      7 (6)                0.16
  Destination after discharge                                                                                                                                       
  Home                                                                20 (27)         146 (34)          0.24      209 (67)          \<0.0001   60 (54)              0.0003
  Another facility, long-term care center, or rehabilitation center   35 (47)         204 (48)          0.97      79 (24)           \<0.0001   40 (36)              0.12
  Median duration of hospitalization,‡ d (range)                      16 (1--143)     11 (0--136)       0.07      6 (0--169)        \<0.0001   9 (1--124)           0.01

\*Values are no. (%) unless otherwise indicated. MRSA, methicillin-resistant *Staphylococcus aureus*; ST, sequence type; NA, not applicable. The p-values were generated to assess whether differences in demographic and risk factor history existed between ST239 and other strains (USA100, USA300, all other strains). χ^2^ tests were used for categorical variables and *t*-tests were used for continuous variables. †Other specialty care unit admitting services included bone marrow, cardiology, hematology, surgical oncology, transplant, and obstetrics and gynecology. ‡Duration of hospitalization and days to MRSA culture--positive included only inpatients; outpatient visits such as clinic or emergency department visits were excluded from the analysis. Duration of hospitalization was calculated from the date of the current hospital admission to the date of discharge. Hospitalization days at another institution before transfer were not included.

Concern for the invasive potential of MRSA ST239-III was illustrated during a 2-year intensive care unit (ICU) outbreak in London in which patients infected with MRSA ST239-III were more likely than patients with non--ST239 strains to show development of bacteremia (47% vs 13%; p\<0.001) and have culture-positive vascular access device infections (59% vs 26%; p\<0.001) ([@R-2-29]). In our study, 19% (14/74) of patients infected with MRSA ST239-III strains were admitted to ICU, compared with 11% (96/850) of patients infected with non--ST239 strains ([Table](#T-2-1){ref-type="table"}). Among MRSA ST239-III ICU admissions, 50% (7/14) were BSIs and 50% (7/14) were LRTIs. The crude mortality rate for persons with BSIs and LRTIs was 22% (8/37) and 47% (9/19) respectively. In our study population, MRSA ST239-III had a higher case-fatality rate than did USA300 (4%) and USA100 (17%) ([Table](#T-2-1){ref-type="table"}).

Increased illness and death for pulmonary disease might be caused by an enhanced ability of MRSA ST239-III strains to produce biofilms and adhere to airway epithelial cells, providing a biologically plausible explanation for its potential to cause pneumonia and central line--associated BSIs ([@R-2-28],[@R-2-29]). The association of MRSA ST239-III isolates with pulmonary infections has also been reported in South Korea ([@R-2-30]). Moreover, in a multicenter study involving 21 hospitals in Beijing, where MRSA ST239-III is especially prevalent, 61% of MRSA LRTI cases were attributed to MRSA ST239-III ([@R-2-31]). The London outbreak strain of MRSA ST239-III, and most examined MRSA ST239-III strains from the People's Republic of China, belong to the same clade (clade II) as the Ohio strain of MRSA ST239-III, demonstrating the potential for this lineage to disseminate and cause disease ([@R-2-9],[@R-2-27],[@R-2-32]). Because of incomplete collection of all MRSA strains causing LRTIs, whether MRSA ST239-III is the prevalent strain in MRSA pneumonias is unknown. A total of 17% (219/1,286) of the study isolates were pulmonary infections and 9% (19/219) of the pneumonias were caused by MRSA ST239-III.

PFGE is the standard for MRSA outbreak investigations. However, we chose a rapid PCR--based method that could serve as a potential screening surveillance tool to identify outbreaks of a particular strain. Although many institutions might be using PFGE for outbreak investigations to identify clonal clusters, methods for PFGE subtype classification are often not standardized between laboratories ([@R-2-33],[@R-2-34]). To maximize uniformity and enable comparisons of PFGE classifications between institutions, the standardized CDC protocols for performing and analyzing PFGE results were used. The initial CDC PFGE analysis classified our isolates as the Brazilian clone. However, SNP typing unambiguously placed the Ohio isolates within a different clade than the Brazilian clone ([Figure 3](#F-2-3){ref-type="fig"}) ([@R-2-9]). Because PFGE typing cannot define specific lineages for MRSA ST239-III, CDC has changed the reporting of MRSA ST239-III strains from Brazilian subtype to ST239. Laboratories will need to perform additional testing to identify specific clades or clonal groups. Classification of the 78 MRSA ST239-III isolates by the traditional PFGE outbreak method would identify only 2 PFGE subtypes instead of the 8 observed patterns. PFGE subtype 1 would consist of isolates A--E, G, and H, and subtype 2 would consist of isolate F ([Figure 1](#F-2-1){ref-type="fig"}, panel B).

Classification issues also exist with respect to the DiversiLab system. Five of the 8 initial rep-PCR patterns matched isolates in the DiversiLab library, which likewise categorized them as the Brazilian clone. In contrast, 3 other rep-PCR patterns did not match any isolates in the DiversiLab library. Additional molecular tests were performed to identify these isolates as MRSA ST239-III.

Because of the novel identification of MRSA ST239-III strains, we performed a battery of molecular tests to better classify the strains. Although the same *dru* types might be found in unrelated MRSA lineages and different staphylococcal species ([@R-2-32]), variation at the *dru* locus within the SCC*mec* III element is consistent with MRSA ST239-III phylogeny ([@R-2-9]). Because use of this typing method is relatively new, further study of its phylogenetic utility is needed ([@R-2-21]). The feasibility of population-based genome-wide SNP datasets has been demonstrated for MRSA ST239-III by Harris et al. ([@R-2-27]). Cluster groupings from these PFGE, rep-PCR, and *dru* methods were not identical, suggesting that the molecular tests are not completely interchangeable. Of the various molecular methods used to index genomic variation in MRSA, *dru* typing and rep-PCR appeared to be more discriminatory.

The publication of only 2 recent reports of MRSA ST239-III in the United States ([@R-2-13],[@R-2-14]) might have resulted from inadequate national surveillance or low transmissibility of the strain. Institutions might not be able to perform genotyping on all their isolates because of lack of appropriate laboratory facilities or resources. An alternative method of surveillance for MRSA ST239-III might be evaluation of the drug susceptibility pattern. Most of the MRSA ST239-III strains in our study were resistant to clindamycin, tetracycline, and gentamicin. In a subset analysis, the phenotypic patterns of antimicrobial drug susceptibility and MRSA genotype prediction were determined for 798 MRSA isolates from the OSHN dataset. Ninety-four percent (63/67) of the MRSA ST239-III isolates were resistant to all 3 drugs (clindamycin, tetracycline, and gentamicin) ([@R-2-35]). Use of phenotypic drug susceptibility patterns might alert infection control practitioners that they are dealing with a MRSA ST239-III clone. Additional molecular testing, such as *spa* typing in conjunction with SCC*mec* typing, can then be performed to confirm the strain type.

We have genotyped and geocoded 1,286 MRSA isolates in the CDC Prevention Epicenter Study by using rep-PCR. The lack of a clear association between MRSA ST239-III molecular genotype patterns could be caused by the retrospective nature of this study, lack of complete population sampling, and the inability to gather social network history. The rep-PCR and PFGE methods might be of limited use in evaluating geographic clustering at the scale studied here unless specific lineages of the reference strains are included in the respective databases. Because of the clonality exhibited by MRSA ST239-III, even a relatively small panel of 43 SNPs is able to identify the same major phylogenetic lineages that are identified by genome-wide SNPs. A more detailed genome-wide SNP analysis might be required to resolve geographic clustering. Additional social networking for determining spatial, temporal, and geographic relationships of patients at the medical institutions studied is under way to identify potential nosocomial interhospital and intrahospital transmission.

Recent identification of a strain of MRSA ST239-III in the midwestern United States is a major public health concern. Globally, this strain has demonstrated increased virulence and widespread dissemination. Because of an inadequate national surveillance system, temporal emergence and dissemination of the strain in the United States is uncertain. The MRSA ST239-III strains in Ohio have molecular heterogeneity and geographic diversity. The SNP-based data suggest that the strains also show clonal diversity. Continued surveillance is warranted because this MRSA ST239-III strain, similar to related strains worldwide, exhibits increased antimicrobial drug resistance, capacity for causing invasive disease, potential for causing outbreaks, and resulting in illnesses and deaths. MRSA ST239-III strains might have the potential to become established locally and disseminate among health care institutions as reported in other regions. Our study underscores the value of molecular surveillance, including traditional fingerprinting methods and newer sequence-based typing methods, as a critical component in understanding the evolving epidemiology of MRSA.
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**1. You are seeing a 65-year-old woman admitted with newly-diagnosed methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia. Which of the following strains of MRSA are most common in the United States?**

A. USA 100 and MRSA ST239-III

B. USA 300 and MRSA ST239-III

C. USA 100 and USA 300

D. USA 600 and MRSA ST239-III

**2. As you evaluate this patient, what should you consider regarding clinical characteristics of MRSA ST239-III in the current study?**

A. Most cases of MRSA ST239-III were diagnosed in community hospitals

B. Ninety-five percent of cases of MRSA ST239-III were health care associated

C. There were no cases of MRSA ST239-III associated with implanted medical devices

D. Nearly all cases of MRSA ST239-III were bloodstream infections

**3. Which of the following statements regarding the treatment and prognosis of MRSA ST239-III in the current study is most accurate?**

A. There was broad susceptibility to nearly all antimicrobials tested

B. Rates of resistance to vancomycin and linezolid were approximately 90%

C. Rates of treatment failure of MRSA ST239-III were significantly higher compared with those associated with USA 100 and USA 300

D. Over 20% of cases of infection with MRSA ST239-III were fatal

**4. Which of the following statements regarding molecular typing of MRSA ST239-III infections in the current study is most accurate?**

A. There was a single repetitive element PCR (rep-PCR) pattern

B. There were 9 different pulsed-field gel electrophoresis (PFGE) patterns

C. Traditional PFGE testing could identify all of the bacteria subtypes

D. The cluster groupings from PFGE, rep-PCR, and dru methods were essentially identical
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